NICE technology appraisal guidance
Issued: August 2008
TA154
Telbivudine for the treatment of chronic hepatitis B
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta154
1 Guidance
This guidance does not apply to people with chronic hepatitis B who also have hepatitis C, hepatitis D or HIV.
1.1 Telbivudine is not recommended for the treatment of chronic hepatitis B.
1.2 People currently receiving telbivudine should have the option to continue therapy until they and their clinicians consider it appropriate to stop.